Controversy

What fraction of published glioma-imaging AI has robust external, multi-scanner, prospective validation

Evidence profile

Status: awaiting_review. Rule: atlas-profile-2.0.

13 linked publications; not a count of independent studies.

Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.

Historical grade: WEAK (retained from 22 September 2026; not a completed profile 2.0 assessment).

Position A

A growing minority of models report external validation and geographic transfer

Position B

Most claims rest on internal cross-validation or single-institution splits; systematic reviews of medical-imaging AI (e.g. head-CT CNN meta-review) find external validation rare, reporting-standard adherence poor, and glioma-specific systematic external-validation evidence even sparser

Clinical stakes

Governs whether any of this reaches deployment; core reproducibility problem

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Editorial lead: Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Page generated 2026-10-02. This is not a new clinical review date.

This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.